COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL
暂无分享,去创建一个
S. Yusuf | M. Ezekowitz | S. Connolly | H. Parise | M. Brueckmann | A. Clemens | L. Wallentin | P. Reilly | Rangadham Nagarakanti | H. Noack | R. Nagarakanti
[1] A. Camm,et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] G. Breithardt,et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial , 2014, European heart journal.
[3] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[4] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[5] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[6] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[7] B. Gersh,et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. , 2010, American heart journal.
[8] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[9] S. Yusuf,et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.
[10] Jennifer G. Robinson,et al. ACCF/AHA TASK FORCE MEMBERS , 2013 .